Eli Lilly and Co. recently announced that it’s spending $1 billion to expand its Limerick, Ireland, manufacturing site. The goal of the expansion, announced Sept. 12, is to increase the production of biologic active ingredients, including those for the company’s recently approved treatment for early symptomatic Alzheimer’s disease. The company announced in July that the…
Roche enters red-hot metabolic disease market with Carmot Therapeutics acquisition
Swiss pharma giant Roche had a limited presence in metabolic disease, but the firm has agreed to take over obesity drug developer Carmot Therapeutics for $2.7 billion, rivaling the dominance of next-gen obesity drug developers Novo Nordisk and Eli Lilly. Carmot had been a rising star in biotech, attracting significant funding, including a $150 million…
Evolving landscape of obesity management could prioritize quality of weight loss over quantity
Obesity drugs seem to be everywhere these days. Just last week, Novo Nordisk announced that it was halting its study of semaglutide early for efficacy. The phase 3b FLOW trial explored the effects of once-weekly injectable semaglutide on kidney outcomes in people with type 2 diabetes (T2D) and chronic kidney disease (CKD). Over the weekend,…